120 related articles for article (PubMed ID: 9585098)
1. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes.
Lewis DF; Lake BG
Toxicology; 1998 Jan; 125(1):31-44. PubMed ID: 9585098
[TBL] [Abstract][Full Text] [Related]
2. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
[TBL] [Abstract][Full Text] [Related]
4. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
5. Additional discussions regarding the altered metabolism and transport of omeprazole after long-term use of St John's wort.
Xie HG
Clin Pharmacol Ther; 2005 Oct; 78(4):440-1. PubMed ID: 16198664
[No Abstract] [Full Text] [Related]
6. Assays of omeprazole metabolism as a substrate probe for human CYP isoforms.
Birkett DJ; Andersson T; Miners JO
Methods Enzymol; 1996; 272():132-9. PubMed ID: 8791770
[No Abstract] [Full Text] [Related]
7. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.
Gonzalez HM; Romero EM; Peregrina AA; de J Chávez T; Escobar-Islas E; Lozano F; Hoyo-Vadillo C
J Clin Pharmacol; 2003 Nov; 43(11):1211-5. PubMed ID: 14551175
[TBL] [Abstract][Full Text] [Related]
8. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
[TBL] [Abstract][Full Text] [Related]
9. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
[TBL] [Abstract][Full Text] [Related]
10. Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone.
Shu Y; Wang LS; Xiao WM; Wang W; Huang SL; Zhou HH
Acta Pharmacol Sin; 2000 Aug; 21(8):753-8. PubMed ID: 11501187
[TBL] [Abstract][Full Text] [Related]
11. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
12. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.
Bertilsson L; Tybring G; Widén J; Chang M; Tomson T
Br J Clin Pharmacol; 1997 Aug; 44(2):186-9. PubMed ID: 9278208
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole.
Abelö A; Andersson TB; Bredberg U; Skånberg I; Weidolf L
Drug Metab Dispos; 2000 Jan; 28(1):58-64. PubMed ID: 10611141
[TBL] [Abstract][Full Text] [Related]
15. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
17. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
[TBL] [Abstract][Full Text] [Related]
18. Prosubstrates of CYP3A4, the major human hepatic cytochrome P450: transformation into substrates by other P450 isoforms.
Stresser DM; Kupfer D
Biochem Pharmacol; 1998 Jun; 55(11):1861-71. PubMed ID: 9714305
[TBL] [Abstract][Full Text] [Related]
19. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Rost KL; Roots I
Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
[TBL] [Abstract][Full Text] [Related]
20. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
